These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 28584152)

  • 1. Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.
    Lepak AJ; Zhao M; Berkow EL; Lockhart SR; Andes DR
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584152
    [No Abstract]   [Full Text] [Related]  

  • 2.
    O'Brien B; Chaturvedi S; Chaturvedi V
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
    Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.
    Maseda E; Grau S; Villagran MJ; Hernandez-Gancedo C; Lopez-Tofiño A; Roberts JA; Aguilar L; Luque S; Sevillano D; Gimenez MJ; Gilsanz F
    J Antimicrob Chemother; 2014 Jun; 69(6):1624-32. PubMed ID: 24505092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
    Cross SA; Scott LJ
    Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent increase in
    Castanheira M; Deshpande LM; Rhomberg PR; Carvalhaes CG
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0057024. PubMed ID: 39264189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candida auris and multidrug resistance: Defining the new normal.
    Lockhart SR
    Fungal Genet Biol; 2019 Oct; 131():103243. PubMed ID: 31228646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
    Kordalewska M; Lee A; Park S; Berrio I; Chowdhary A; Zhao Y; Perlin DS
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632013
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
    Xu G; Zhu L; Liao S; Ge T; Yang J
    Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution.
    Liew YX; Teo J; Too IA; Ngan CC; Tan AL; Chlebicki MP; Kwa AL; Lee W
    BMC Infect Dis; 2015 Jul; 15():256. PubMed ID: 26137997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro pharmacodynamics and in vivo efficacy of fluconazole, amphotericin B and caspofungin in a murine infection by Candida lusitaniae.
    Sandoval-Denis M; Pastor FJ; Capilla J; Sutton DA; Fothergill AW; Guarro J
    Int J Antimicrob Agents; 2014 Feb; 43(2):161-4. PubMed ID: 24360922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
    Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
    Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis.
    Pea F
    Mycoses; 2020 Aug; 63(8):854-858. PubMed ID: 32472719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.
    Louie A; Banerjee P; Drusano GL; Shayegani M; Miller MH
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2841-7. PubMed ID: 10582869
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Zhao M; Lepak AJ; VanScoy B; Bader JC; Marchillo K; Vanhecker J; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients.
    Scott LJ
    Paediatr Drugs; 2017 Feb; 19(1):81-90. PubMed ID: 28083856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.
    Andes DR; Reynolds DK; Van Wart SA; Lepak AJ; Kovanda LL; Bhavnani SM
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5714-6. PubMed ID: 23959319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.
    Lepak AJ; Zhao M; Andes DR
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
    Andes DR; Diekema DJ; Pfaller MA; Marchillo K; Bohrmueller J
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.